Research ExplorerPublicationsCD40 activation in vivo overcomes peptide-induced peripheral...

CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy

Standard

CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. / Diehl, L; den Boer, A T; Schoenberger, S P; van der Voort, E I; Schumacher, T N; Melief, C J; Offringa, R; Toes, R E.

In: NAT MED, Vol. 5, No. 7, 07.1999, p. 774-9.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Diehl, L, den Boer, AT, Schoenberger, SP, van der Voort, EI, Schumacher, TN, Melief, CJ, Offringa, R & Toes, RE 1999, 'CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy', NAT MED, vol. 5, no. 7, pp. 774-9. https://doi.org/10.1038/10495

APA

Diehl, L., den Boer, A. T., Schoenberger, S. P., van der Voort, E. I., Schumacher, T. N., Melief, C. J., Offringa, R., & Toes, R. E. (1999). CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. NAT MED, 5(7), 774-9. https://doi.org/10.1038/10495

Vancouver

Diehl L, den Boer AT, Schoenberger SP, van der Voort EI, Schumacher TN, Melief CJ et al. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. NAT MED. 1999 Jul;5(7):774-9. https://doi.org/10.1038/10495

Bibtex

@article{f750afc281e34c83b18e4ea7f940416a,
title = "CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy",
abstract = "The outcome of antigen recognition by naive CD8+ cytotoxic T lymphocytes (CTLs) in the periphery is orchestrated by CD4+ T-helper cells, and can either lead to priming or tolerization. The presence of T-helper cells favors the induction of CTL immunity, whereas the absence of T-helper cells can result in CTL tolerance. The action of T helper cells in CTL priming is mediated by CD40-CD40 ligand interactions. We demonstrate here that triggering of CD40 in vivo can considerably enhance the efficacy of peptide-based anti-tumor vaccines. The combination of a tolerogenic peptide vaccine containing a minimal essential CTL epitope with an activating antibody against CD40 converts tolerization into strong CTL priming. Moreover, CD40 ligation can provide an already protective tumor-specific peptide vaccine with the capacity to induce therapeutic CTL immunity in tumor-bearing mice. These findings indicate that the CD40-CD40 ligand pair can act as a 'switch', determining whether naive peripheral CTLs are primed or tolerized, and support the clinical use of CD40-stimulating agents as components of anti-cancer vaccines.",
keywords = "Adenovirus E1A Proteins, Animals, Antigens, CD40, B-Lymphocytes, CD40 Ligand, Cancer Vaccines, Cell Transformation, Neoplastic, Epitopes, Immune Tolerance, Lymphocyte Activation, Membrane Glycoproteins, Mice, Mice, Inbred C57BL, Mice, Knockout, Neoplasms, Experimental, Peptide Fragments, Spleen, T-Lymphocytes, Cytotoxic, T-Lymphocytes, Helper-Inducer",
author = "L Diehl and {den Boer}, {A T} and Schoenberger, {S P} and {van der Voort}, {E I} and Schumacher, {T N} and Melief, {C J} and R Offringa and Toes, {R E}",
year = "1999",
month = jul,
doi = "10.1038/10495",
language = "English",
volume = "5",
pages = "774--9",
journal = "NAT MED",
issn = "1078-8956",
publisher = "NATURE PUBLISHING GROUP",
number = "7",

}

RIS

TY - JOUR

T1 - CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy

AU - Diehl, L

AU - den Boer, A T

AU - Schoenberger, S P

AU - van der Voort, E I

AU - Schumacher, T N

AU - Melief, C J

AU - Offringa, R

AU - Toes, R E

PY - 1999/7

Y1 - 1999/7

N2 - The outcome of antigen recognition by naive CD8+ cytotoxic T lymphocytes (CTLs) in the periphery is orchestrated by CD4+ T-helper cells, and can either lead to priming or tolerization. The presence of T-helper cells favors the induction of CTL immunity, whereas the absence of T-helper cells can result in CTL tolerance. The action of T helper cells in CTL priming is mediated by CD40-CD40 ligand interactions. We demonstrate here that triggering of CD40 in vivo can considerably enhance the efficacy of peptide-based anti-tumor vaccines. The combination of a tolerogenic peptide vaccine containing a minimal essential CTL epitope with an activating antibody against CD40 converts tolerization into strong CTL priming. Moreover, CD40 ligation can provide an already protective tumor-specific peptide vaccine with the capacity to induce therapeutic CTL immunity in tumor-bearing mice. These findings indicate that the CD40-CD40 ligand pair can act as a 'switch', determining whether naive peripheral CTLs are primed or tolerized, and support the clinical use of CD40-stimulating agents as components of anti-cancer vaccines.

AB - The outcome of antigen recognition by naive CD8+ cytotoxic T lymphocytes (CTLs) in the periphery is orchestrated by CD4+ T-helper cells, and can either lead to priming or tolerization. The presence of T-helper cells favors the induction of CTL immunity, whereas the absence of T-helper cells can result in CTL tolerance. The action of T helper cells in CTL priming is mediated by CD40-CD40 ligand interactions. We demonstrate here that triggering of CD40 in vivo can considerably enhance the efficacy of peptide-based anti-tumor vaccines. The combination of a tolerogenic peptide vaccine containing a minimal essential CTL epitope with an activating antibody against CD40 converts tolerization into strong CTL priming. Moreover, CD40 ligation can provide an already protective tumor-specific peptide vaccine with the capacity to induce therapeutic CTL immunity in tumor-bearing mice. These findings indicate that the CD40-CD40 ligand pair can act as a 'switch', determining whether naive peripheral CTLs are primed or tolerized, and support the clinical use of CD40-stimulating agents as components of anti-cancer vaccines.

KW - Adenovirus E1A Proteins

KW - Animals

KW - Antigens, CD40

KW - B-Lymphocytes

KW - CD40 Ligand

KW - Cancer Vaccines

KW - Cell Transformation, Neoplastic

KW - Epitopes

KW - Immune Tolerance

KW - Lymphocyte Activation

KW - Membrane Glycoproteins

KW - Mice

KW - Mice, Inbred C57BL

KW - Mice, Knockout

KW - Neoplasms, Experimental

KW - Peptide Fragments

KW - Spleen

KW - T-Lymphocytes, Cytotoxic

KW - T-Lymphocytes, Helper-Inducer

U2 - 10.1038/10495

DO - 10.1038/10495

M3 - SCORING: Journal article

C2 - 10395322

VL - 5

SP - 774

EP - 779

JO - NAT MED

JF - NAT MED

SN - 1078-8956

IS - 7

ER -